Apyx Medical Corporation (APYX)
| Market Cap | 124.69M +57.0% |
| Revenue (ttm) | 58.42M +25.6% |
| Net Income | -8.63M |
| EPS | -0.20 |
| Shares Out | 42.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,079 |
| Open | 3.030 |
| Previous Close | 3.020 |
| Day's Range | 2.900 - 3.030 |
| 52-Week Range | 1.700 - 5.080 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 6.60 (+122.97%) |
| Earnings Date | Aug 6, 2026 |
About APYX
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparo... [Read more]
Financial Performance
In 2025, Apyx Medical's revenue was $52.84 million, an increase of 9.86% compared to the previous year's $48.10 million. Losses were -$11.21 million, -52.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for APYX stock is "Strong Buy." The 12-month stock price target is $6.6, which is an increase of 122.97% from the latest price.
News
Apyx Medical Slides: Investor presentation
Apyx Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 28, 2026.
Apyx Medical Transcript: Canaccord Genuity's 46th Annual Growth Conference
GLP-1 drugs are driving a new wave of demand for surgical aesthetics, especially skin tightening and body contouring. The AYON system, integrating multiple advanced technologies, is positioned for strong growth, with international expansion and profitability as key goals.
Apyx Medical reports Q2 EPS (7c), consensus (8c)
Reports Q2 revenue $13.88M, consensus $13.18M. “We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strate...
Apyx Medical backs FY26 revenue view $59M-$60M, consensus $59.55M
The company said, “The Company continues to expect operating expenses of less than $45.0 million for the year ended December 31, 2026.”
Apyx Medical Earnings Call Transcript: Q2 2026
Revenue grew 22% year-over-year to $13.9M, led by AYON platform adoption and strong surgical aesthetics sales. Gross margin improved to 63.9%, and net loss narrowed. Full-year guidance reaffirmed, with liquidity expected into 2028.
Apyx Medical Earnings release: Q2 2026
Apyx Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Apyx Medical Quarterly report: Q2 2026
Apyx Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYO...
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the...
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the A...
Apyx Medical initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Yi Chen initiated coverage of Apyx Medical (APYX) with a Buy rating and $7 price target Apyx is a commercial stage surgical aesthetics company developing advanced energy-based…
Apyx Medical management to meet with Citizens
Meeting to be held on July 14 hosted by Citizens.
Apyx Medical Proxy statement: Proxy filing
Apyx Medical filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
Apyx Medical Slides: Investor presentation
Apyx Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
CLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON B...
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Published data demonstrates visible reduction in dimpling and progressive ...
Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AY...
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON Addition of the power liposuction capability as a second...
Apyx Medical reports Q1 EPS (5c), consensus (11c)
Reports Q1 revenue $12.49M, consensus $10.77M. “Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S....
Apyx Medical raises FY26 revenue view to $59M-$60M from $57.5M-$58.5M
Consensus $57.84M. Backs FY26 operating expenses view less than $45M.
Apyx Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 32% year-over-year to $12.5M, led by AYON system sales and strong international demand. Gross margin improved to 63.5%, and full-year guidance was raised to $59–$60M. AYON adoption is early, with FDA clearance for power liposuction expected soon.
Apyx Medical Earnings release: Q1 2026
Apyx Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Apyx Medical Quarterly report: Q1 2026
Apyx Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON...
Weight-loss revolution sparks new appetite for aesthetics firms
Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quart...